J N Ingle
Overview
Explore the profile of J N Ingle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
161
Citations
2489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Liu C, Erlichman C, McDonald C, Ingle J, Zollman P, Iankov I, et al.
Gene Ther
. 2008 Mar;
15(14):1024-34.
PMID: 18356818
Oncolytic measles virus strains have activity against multiple tumor types and are currently in phase I clinical testing. Induction of the heat shock protein 70 (HSP70) constitutes one of the...
12.
Ingle J, Tu D, Pater J, Muss H, Martino S, Robert N, et al.
Ann Oncol
. 2008 Mar;
19(5):877-82.
PMID: 18332043
Background: MA.17 evaluated letrozole or placebo after 5 years of tamoxifen and showed significant improvement in disease-free survival (DFS) for letrozole [hazard ratio (HR) 0.57, P = 0.00008]. The trial...
13.
Hawse J, Subramaniam M, Ingle J, Oursler M, Rajamannan N, Spelsberg T
J Cell Biochem
. 2007 Jun;
103(2):383-92.
PMID: 17541956
It is well established that E(2) and TGFbeta have major biological effects in multiple tissues, including bone. The signaling pathways through which these two factors elicit their effects are well...
14.
Vachon C, Ingle J, Suman V, Scott C, Gottardt H, Olson J, et al.
Breast
. 2006 Dec;
16(2):204-10.
PMID: 17145182
Breast density, a strong risk factor for breast cancer, is reduced by the anti-estrogen, tamoxifen (TAM). We examined whether aromatase inhibitor (AI) therapy results in further reductions in breast density...
15.
Moy B, Tu D, Pater J, Ingle J, Shepherd L, Whelan T, et al.
Ann Oncol
. 2006 Aug;
17(11):1637-43.
PMID: 16936184
Background: Aromatase inhibitors are widely employed in the adjuvant treatment of early stage breast cancer. The impact of aromatase inhibitors has not been established in ethnic minority women. Patients And...
16.
Ma C, Steen P, Rowland K, Niedringhaus R, Fitch T, Kugler J, et al.
Ann Oncol
. 2005 Nov;
17(2):226-31.
PMID: 16303865
Purpose: This phase II study was undertaken to define the efficacy and toxicity of pemetrexed in combination with gemcitabine in patients with metastatic breast cancer. Patients And Methods: Patients with...
17.
Wasan K, Goss P, Pritchard P, Shepherd L, Palmer M, Liu S, et al.
Ann Oncol
. 2005 Apr;
16(5):707-15.
PMID: 15817595
Background: The purpose of this study was to evaluate changes in serum lipid parameters {cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and lipoprotein(a) [Lp(a)]}, in postmenopausal women...
18.
Adem C, Reynolds C, Ingle J, Nascimento A
Br J Cancer
. 2004 Jun;
91(2):237-41.
PMID: 15187996
Primary sarcomas of the breast are extremely rare, with less than 0.1% of all malignant tumours of the breast. Mayo Clinic Surgical Pathology database was searched for all breast sarcoma...
19.
Perez E, Geeraerts L, Suman V, Adjei A, Baron A, Hatfield A, et al.
Ann Oncol
. 2002 Aug;
13(8):1225-35.
PMID: 12181246
Background: Docetaxel has yielded promising response rates as a component of doxorubicin-based combination schedules in patients with metastatic breast cancer, including docetaxel/doxorubicin and docetaxel/doxorubicin/cyclophosphamide (AC). This randomized two-stage phase II...
20.
Ingle J
Clin Cancer Res
. 2002 Mar;
7(12 Suppl):4392s-4396s; discussion 4411s-4412s.
PMID: 11916230
Adjuvant endocrine therapy is a vitally important modality for treatment of women with resected hormone-sensitive breast cancer as indicated by the presence of estrogen and/or progesterone receptors in the tumor....